Interoperability Standards Priorities Task Force

Ken Kawamoto, Co-Chair
Steven Lane, Co-Chair
July 9, 2019
Agenda

• Call to Order/Roll Call
  ➢ Lauren Richie, Designated Federal Officer, ONC
• Medication Recommendations
  ➢ Steven Lane, Task Force Co-Chair
• Patient Transparency
  ➢ Kim Diehl Boyd (CoverMyMeds)
• ISP Task Force Recommendations- Next Steps
  ➢ Steven Lane, Task Force Co-Chair
• Discussion
  ➢ Steven Lane, Task Force Co-Chair
• Public Comment
ISP Task Force Charge

• **Overarching Charge:** To make recommendations on priority uses of health information technology and the associated standards and implementation specifications that support such uses.

• **Specific Charge:** The ISP Task Force will:

  1. Make recommendations on the following:
     - Priority uses of health IT (consistent with the Cures Act’s identified priorities);
     - The standards and implementation specifications that best support or may need to be developed for each identified priority; and
     - Subsequent steps for industry and government action.

  2. Publish a report summarizing its findings.
<table>
<thead>
<tr>
<th>Name</th>
<th>Organization/Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ken Kawamoto, MD, Co-Chair</td>
<td>University of Utah Health</td>
</tr>
<tr>
<td>Ricky Bloomfield, MD</td>
<td>Apple</td>
</tr>
<tr>
<td>Tamer Fakhouri, MD</td>
<td>Livongo Health</td>
</tr>
<tr>
<td>Valerie Grey, MS</td>
<td>New York eHealth Collaborative</td>
</tr>
<tr>
<td>Anil K. Jain, MD</td>
<td>IBM Watson Health</td>
</tr>
<tr>
<td>Leslie Lenert, MD</td>
<td>Medical University of South Carolina</td>
</tr>
<tr>
<td>David McCallie, Jr., MD</td>
<td>Individual</td>
</tr>
<tr>
<td>Terrence O’Malley, MD</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>Raj Ratwani, MA, PhD</td>
<td>MedStar Health</td>
</tr>
<tr>
<td>Sasha TerMaat, BA</td>
<td>Epic</td>
</tr>
<tr>
<td>Steven Lane, MD, Co-Chair</td>
<td>Sutter Health</td>
</tr>
<tr>
<td>Tina Esposito, MBA, RHIA, FACHE</td>
<td>Advocate Aurora Health</td>
</tr>
<tr>
<td>Cynthia A. Fisher, D.Sc, MBA</td>
<td>WaterRev, LLC</td>
</tr>
<tr>
<td>Edward Juhn, MD, MBA, MPH</td>
<td>Blue Shield of California</td>
</tr>
<tr>
<td>Victor Lee, MD</td>
<td>Clinical Architecture</td>
</tr>
<tr>
<td>Arien Malec</td>
<td>Change Healthcare</td>
</tr>
<tr>
<td>Clem McDonald, MD</td>
<td>National Library of Medicine</td>
</tr>
<tr>
<td>Ming Jack Po, MD, PhD</td>
<td>Google</td>
</tr>
<tr>
<td>Ram Sriram, PhD</td>
<td>National Institute of Standards and Technology</td>
</tr>
<tr>
<td>Andrew Truscott</td>
<td>Accenture</td>
</tr>
</tbody>
</table>
Priority 1:

- Medication Reconciliation
- Discrete/Structured Medication Sigs
- Medication Administration & Dispense History Data
- Real Price Data for Medications
- Eligibility & Formulary Checking Transactions
- Electronic Prior Authorization (Prescription Benefit)
- Alternative Therapies Information
- Electronic Prescribing of Controlled Substances
Topic Areas-Medication Recommendations

Priority 2:

• Costs to access to PDMP Data
• Adverse Drug Event Detection
• PDMP Query and Reporting Transactions
• Prescription Transfer Transactions
• Electronic Prior Authorization (Medical Benefit)
• RxNorm Code availability for discontinued drugs
• Public access to NCPDP standards
• Risk Evaluation and Mitigation Strategy Data
Patient Transparency

Kim Diehl-Boyd (CoverMyMeds)
Discussion

*Steven Lane, Task Force Co-Chair*
To make a comment please call:

Dial: 1-877-407-7192

(once connected, press “*1” to speak)

All public comments will be limited to three minutes.

You may enter a comment in the “Public Comment” field below this presentation.

Or, email your public comment to onc-hitac@accelsolutionsllc.com.

Written comments will not be read at this time, but they will be delivered to members of the Workgroup and made part of the Public Record.
Questions